RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT is closing two Phase II trials for Rapt’s lead candidate, zelnecirnon, three months after the FDA placed a clinical hold on them.
RAPT is closing two Phase II trials for Rapt’s lead candidate, zelnecirnon, three months after the FDA placed a clinical hold on them.
Rakovina has expanded research collaborations with Pharma Inventor and the University of British Columbia to identify novel drug candidates.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Biotechs must prioritise ethics to deter GenAI “bad actors”
AstraZeneca to withdraw Covid-19 vaccine globally
GSK, Lundbeck, ROVI: Three Journeys of Unified Pharma Events Management
NIH team develops AI tool to predict cancer drug response